JP2016539996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539996A5 JP2016539996A5 JP2016538524A JP2016538524A JP2016539996A5 JP 2016539996 A5 JP2016539996 A5 JP 2016539996A5 JP 2016538524 A JP2016538524 A JP 2016538524A JP 2016538524 A JP2016538524 A JP 2016538524A JP 2016539996 A5 JP2016539996 A5 JP 2016539996A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- nitrogen
- sulfur
- oxygen
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 96
- 229910052757 nitrogen Inorganic materials 0.000 description 50
- 125000005842 heteroatom Chemical group 0.000 description 47
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 46
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 46
- 229910052760 oxygen Inorganic materials 0.000 description 46
- 239000001301 oxygen Substances 0.000 description 46
- 229910052717 sulfur Inorganic materials 0.000 description 46
- 239000011593 sulfur Substances 0.000 description 46
- 150000001875 compounds Chemical class 0.000 description 45
- 0 *C(*(*)C(*)=O)C(**1)=C(*)*C1=C1*C(N*)=N**1 Chemical compound *C(*(*)C(*)=O)C(**1)=C(*)*C1=C1*C(N*)=N**1 0.000 description 41
- 229920006395 saturated elastomer Polymers 0.000 description 37
- 125000001931 aliphatic group Chemical group 0.000 description 21
- 229910052736 halogen Inorganic materials 0.000 description 20
- 150000002367 halogens Chemical class 0.000 description 20
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- ZBOAVARJHVEXAV-VYPXRBNDSA-N C/C(/C=N)=C/NC(CC1)CCC1C(O)=O Chemical compound C/C(/C=N)=C/NC(CC1)CCC1C(O)=O ZBOAVARJHVEXAV-VYPXRBNDSA-N 0.000 description 2
- ZPPAFGGDEWACHQ-UHFFFAOYSA-N CC(C)(C)c1ncc(C)[s]1 Chemical compound CC(C)(C)c1ncc(C)[s]1 ZPPAFGGDEWACHQ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FLWMZUZXOCURSQ-UHFFFAOYSA-N Cc1n[n](CCC2)c2c1 Chemical compound Cc1n[n](CCC2)c2c1 FLWMZUZXOCURSQ-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- ALBOIKUQWILHBQ-ALCCZGGFSA-N CC(C(C(S/C(/C)=C\N)=C)(F)F)=C Chemical compound CC(C(C(S/C(/C)=C\N)=C)(F)F)=C ALBOIKUQWILHBQ-ALCCZGGFSA-N 0.000 description 1
- LMVHALAYUBESJG-UHFFFAOYSA-N CC(C)(C)C1CNCC1 Chemical compound CC(C)(C)C1CNCC1 LMVHALAYUBESJG-UHFFFAOYSA-N 0.000 description 1
- ZGMZDUWNJFJZAW-NSLJVHTKSA-N CC(C)/C(/C=N)=C/NC Chemical compound CC(C)/C(/C=N)=C/NC ZGMZDUWNJFJZAW-NSLJVHTKSA-N 0.000 description 1
- ALUVICSBTSCGOM-KHPPLWFESA-N CCC/C(/SC(C(C)(C)C)=C)=C(\CN)/N Chemical compound CCC/C(/SC(C(C)(C)C)=C)=C(\CN)/N ALUVICSBTSCGOM-KHPPLWFESA-N 0.000 description 1
- WYUIWKFIFOJVKW-UHFFFAOYSA-N Cc(cc1)cc(Cl)c1Cl Chemical compound Cc(cc1)cc(Cl)c1Cl WYUIWKFIFOJVKW-UHFFFAOYSA-N 0.000 description 1
- PTLTZFJYSSVFEC-UHFFFAOYSA-N Cc1cc(CNCC2)c2[s]1 Chemical compound Cc1cc(CNCC2)c2[s]1 PTLTZFJYSSVFEC-UHFFFAOYSA-N 0.000 description 1
- KUFCFZFIBCYHQN-UHFFFAOYSA-N Cc1cc(COCC2)c2[s]1 Chemical compound Cc1cc(COCC2)c2[s]1 KUFCFZFIBCYHQN-UHFFFAOYSA-N 0.000 description 1
- LCERCHDXDTXTEA-UHFFFAOYSA-N Cc1cc(NCCC2)c2[s]1 Chemical compound Cc1cc(NCCC2)c2[s]1 LCERCHDXDTXTEA-UHFFFAOYSA-N 0.000 description 1
- UFISOUUWLYZFEX-UHFFFAOYSA-N Cc1cc(OCCC2)c2[s]1 Chemical compound Cc1cc(OCCC2)c2[s]1 UFISOUUWLYZFEX-UHFFFAOYSA-N 0.000 description 1
- ZBCOTWQYKCHKQK-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)cn1 Chemical compound Cc1ccc(C(F)(F)F)cn1 ZBCOTWQYKCHKQK-UHFFFAOYSA-N 0.000 description 1
- DQMSQXZUGHBBDL-UHFFFAOYSA-N Cc1nc(CCCC2)c2[s]1 Chemical compound Cc1nc(CCCC2)c2[s]1 DQMSQXZUGHBBDL-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- RDRQUUWCJTYHCT-UHFFFAOYSA-N FC(C1CCNCC1)(F)F Chemical compound FC(C1CCNCC1)(F)F RDRQUUWCJTYHCT-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- -1 piperizinyl Chemical group 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914886P | 2013-12-11 | 2013-12-11 | |
| US61/914,886 | 2013-12-11 | ||
| PCT/US2014/069853 WO2015089337A1 (en) | 2013-12-11 | 2014-12-11 | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236092A Division JP6526167B2 (ja) | 2013-12-11 | 2017-12-08 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539996A JP2016539996A (ja) | 2016-12-22 |
| JP2016539996A5 true JP2016539996A5 (enExample) | 2018-01-25 |
| JP6431914B2 JP6431914B2 (ja) | 2018-11-28 |
Family
ID=52302344
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538524A Active JP6431914B2 (ja) | 2013-12-11 | 2014-12-11 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| JP2017236092A Active JP6526167B2 (ja) | 2013-12-11 | 2017-12-08 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| JP2019087573A Withdrawn JP2019163280A (ja) | 2013-12-11 | 2019-05-07 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| JP2021041198A Active JP7076022B2 (ja) | 2013-12-11 | 2021-03-15 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236092A Active JP6526167B2 (ja) | 2013-12-11 | 2017-12-08 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| JP2019087573A Withdrawn JP2019163280A (ja) | 2013-12-11 | 2019-05-07 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
| JP2021041198A Active JP7076022B2 (ja) | 2013-12-11 | 2021-03-15 | 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物 |
Country Status (32)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE043522T2 (hu) * | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| KR102413253B1 (ko) * | 2013-12-11 | 2022-06-27 | 바이오젠 엠에이 인코포레이티드 | 종양, 신경 및 면역에서 인간 질환을 치료하는데 유용한 바이아릴 화합물 |
| US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| US20180179189A1 (en) * | 2015-06-10 | 2018-06-28 | Biogen Ma Inc. | Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| AU2016368257C1 (en) * | 2015-12-07 | 2019-12-05 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Five-membered heterocyclic amides wnt pathway inhibitor |
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| CN118147079A (zh) * | 2016-03-31 | 2024-06-07 | 来恩生物医药私人有限公司 | 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞 |
| EP3476848A4 (en) * | 2016-06-27 | 2020-01-15 | Hangzhou Rex Pharmaceutical Co., Ltd | BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR |
| EP3487852A1 (en) | 2016-07-21 | 2019-05-29 | Biogen MA Inc. | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
| JP7076741B2 (ja) | 2016-12-27 | 2022-05-30 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| CN112262137A (zh) | 2018-01-10 | 2021-01-22 | 阿林齐生物制药公司 | 四氢异喹啉化合物 |
| TWI835770B (zh) | 2018-01-19 | 2024-03-21 | 美商胞質動力學公司 | 心肌節抑制劑 |
| US20190330226A1 (en) * | 2018-04-26 | 2019-10-31 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US10899753B2 (en) | 2018-05-14 | 2021-01-26 | Biogen Ma Inc. | Inhibiting agents for Bruton's tyrosine kinase |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| CA3224985A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| JP7476214B2 (ja) * | 2018-10-15 | 2024-04-30 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の結晶多形 |
| WO2020118683A1 (en) * | 2018-12-14 | 2020-06-18 | Lynk Pharmaceuticals Co. Ltd. | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| JP7747523B2 (ja) * | 2019-05-15 | 2025-10-01 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| CN110627775A (zh) * | 2019-10-24 | 2019-12-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| US20230121818A1 (en) * | 2019-12-23 | 2023-04-20 | Biogen Ma Inc. | Btk inhibitors |
| CN116917279A (zh) * | 2020-08-07 | 2023-10-20 | 渤健马萨诸塞州股份有限公司 | Btk抑制剂 |
| UY39370A (es) * | 2020-08-07 | 2022-02-25 | Biogen Ma Inc | Inhibidores de la btk |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| TW202317558A (zh) * | 2021-06-21 | 2023-05-01 | 英屬開曼群島商百濟神州有限公司 | （ｒ）－戊二醯亞胺ｃｒｂｎ配位體及使用方法 |
| AU2022424178A1 (en) * | 2021-12-30 | 2024-07-11 | Beone Medicines I Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| CN116891437B (zh) * | 2022-04-06 | 2025-10-28 | 长春金赛药业有限责任公司 | 氨基酸衍生物、药物组合物及其制备方法和应用 |
| WO2024146923A1 (en) | 2023-01-04 | 2024-07-11 | Ab Science | Tubulin polymerization inhibitors |
| CN117088851A (zh) * | 2023-07-13 | 2023-11-21 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US833429A (en) * | 1902-07-31 | 1906-10-16 | Anthony Van Wagenen | Automatic system of intercommunication. |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE69212850T2 (de) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| MXPA03001226A (es) * | 2000-08-08 | 2004-09-10 | Johnson & Johnson | Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados. |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| GB0325031D0 (en) * | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| EP1713775A4 (en) * | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| DK1951684T3 (en) * | 2005-11-01 | 2016-10-24 | Targegen Inc | BIARYLMETAPYRIMIDIN kinase inhibitors |
| UA109411C2 (uk) * | 2005-11-01 | 2015-08-25 | N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки | |
| WO2007089768A2 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| CA2668338A1 (en) * | 2006-11-01 | 2008-05-08 | Chroma Therapeutics Ltd. | Ikk-.beta. serine-threonine protein kinase inhibitors |
| CN101730699A (zh) * | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
| US8809273B2 (en) * | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| KR20160116045A (ko) * | 2007-10-05 | 2016-10-06 | 베라스템, 인코포레이티드 | 피리미딘 치환된 퓨린 유도체 |
| JP5743897B2 (ja) * | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 化合物 |
| US9029359B2 (en) * | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| HUE043522T2 (hu) * | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
| US8334292B1 (en) * | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| JP2014500254A (ja) | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
| EP2548622B1 (en) | 2011-03-31 | 2015-06-17 | Mizuno Corporation | Iron golf club head and iron golf club |
| CA2832919A1 (en) | 2011-04-12 | 2012-10-18 | Ryan C. Holcomb | Compounds, compositions, and therapeutic uses thereof |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| KR102413253B1 (ko) | 2013-12-11 | 2022-06-27 | 바이오젠 엠에이 인코포레이티드 | 종양, 신경 및 면역에서 인간 질환을 치료하는데 유용한 바이아릴 화합물 |
| EP3080122B1 (en) | 2013-12-11 | 2018-10-31 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| AU2015268962A1 (en) * | 2014-06-04 | 2017-01-12 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| ES2907622T3 (es) * | 2014-10-06 | 2022-04-25 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de BTK y usos de estos |
| US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
-
2014
- 2014-12-11 KR KR1020167018533A patent/KR102413253B1/ko active Active
- 2014-12-11 HU HUE14825001A patent/HUE040346T2/hu unknown
- 2014-12-11 RS RS20180830A patent/RS57662B1/sr unknown
- 2014-12-11 EP EP21168048.3A patent/EP3872075A1/en active Pending
- 2014-12-11 EP EP18160575.9A patent/EP3357921A3/en not_active Withdrawn
- 2014-12-11 WO PCT/US2014/069853 patent/WO2015089337A1/en not_active Ceased
- 2014-12-11 AU AU2014362231A patent/AU2014362231B2/en active Active
- 2014-12-11 MX MX2016007611A patent/MX370103B/es active IP Right Grant
- 2014-12-11 MX MX2019014228A patent/MX388978B/es unknown
- 2014-12-11 HR HRP20181109TT patent/HRP20181109T1/hr unknown
- 2014-12-11 EP EP14825001.2A patent/EP3080103B9/en active Active
- 2014-12-11 US US15/103,749 patent/US9809577B2/en active Active
- 2014-12-11 AR ARP140104620A patent/AR098721A1/es active IP Right Grant
- 2014-12-11 TW TW106124589A patent/TWI675833B/zh active
- 2014-12-11 CN CN201480071422.6A patent/CN106459002B/zh active Active
- 2014-12-11 CN CN201810840975.3A patent/CN108947913A/zh active Pending
- 2014-12-11 EA EA201792348A patent/EA037942B1/ru unknown
- 2014-12-11 ES ES14825001.2T patent/ES2678021T3/es active Active
- 2014-12-11 NZ NZ721217A patent/NZ721217A/en unknown
- 2014-12-11 MY MYPI2016702033A patent/MY179781A/en unknown
- 2014-12-11 DK DK14825001.2T patent/DK3080103T3/en active
- 2014-12-11 PL PL14825001T patent/PL3080103T3/pl unknown
- 2014-12-11 LT LTEP14825001.2T patent/LT3080103T/lt unknown
- 2014-12-11 BR BR112016012860A patent/BR112016012860A2/pt not_active Application Discontinuation
- 2014-12-11 PT PT148250012T patent/PT3080103T/pt unknown
- 2014-12-11 SG SG10201908558W patent/SG10201908558WA/en unknown
- 2014-12-11 SI SI201430795T patent/SI3080103T1/sl unknown
- 2014-12-11 SM SM20180373T patent/SMT201800373T1/it unknown
- 2014-12-11 EA EA201691114A patent/EA030538B1/ru unknown
- 2014-12-11 TW TW103143378A patent/TWI608002B/zh active
- 2014-12-11 CA CA2932608A patent/CA2932608C/en active Active
- 2014-12-11 CN CN201810840784.7A patent/CN109096274B/zh active Active
- 2014-12-11 SG SG11201604595VA patent/SG11201604595VA/en unknown
- 2014-12-11 JP JP2016538524A patent/JP6431914B2/ja active Active
- 2014-12-11 TW TW108127236A patent/TWI744672B/zh active
-
2016
- 2016-06-05 IL IL24603116A patent/IL246031B/en active IP Right Grant
- 2016-06-09 SA SA518391170A patent/SA518391170B1/ar unknown
- 2016-06-10 CL CL2016001435A patent/CL2016001435A1/es unknown
- 2016-06-10 PH PH12016501107A patent/PH12016501107B1/en unknown
-
2017
- 2017-06-08 CL CL2017001459A patent/CL2017001459A1/es unknown
- 2017-09-08 US US15/699,857 patent/US10081619B2/en active Active
- 2017-09-14 ZA ZA2017/06244A patent/ZA201706244B/en unknown
- 2017-12-08 JP JP2017236092A patent/JP6526167B2/ja active Active
- 2017-12-15 AR ARP170103535A patent/AR110381A2/es unknown
-
2018
- 2018-07-18 CY CY20181100755T patent/CY1120517T1/el unknown
- 2018-08-22 US US16/108,755 patent/US10759783B2/en active Active
-
2019
- 2019-03-22 AU AU2019201997A patent/AU2019201997C1/en active Active
- 2019-05-07 JP JP2019087573A patent/JP2019163280A/ja not_active Withdrawn
- 2019-09-23 IL IL269569A patent/IL269569B/en active IP Right Grant
-
2020
- 2020-08-27 US US17/004,411 patent/US11572356B2/en active Active
-
2021
- 2021-03-15 JP JP2021041198A patent/JP7076022B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539996A5 (enExample) | ||
| JP2015518903A5 (enExample) | ||
| JP2016536363A5 (enExample) | ||
| JP2017511357A5 (enExample) | ||
| JP2016536364A5 (enExample) | ||
| KR102376354B1 (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| JP2016526024A5 (enExample) | ||
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| JP2017536369A5 (enExample) | ||
| JP2017506675A5 (enExample) | ||
| JP2018538248A5 (enExample) | ||
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| BR112015005331B8 (pt) | Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo | |
| EP4495093A3 (en) | Polycyclic compound and organic eletroluminescence device including the same | |
| PE20160995A1 (es) | Inhibidores de syk | |
| JP2015535277A5 (enExample) | ||
| NZ590474A (en) | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | |
| EA201692461A1 (ru) | Прокатализатор для полимеризации олефинов | |
| JP2016520065A5 (enExample) | ||
| JP2016537382A5 (enExample) | ||
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| JP2019510794A5 (enExample) | ||
| JP2016518448A5 (enExample) | ||
| RU2016137668A (ru) | Новые производные каннабидиол-хинона | |
| EP3450014A4 (en) | CATALYST FOR THE CHLORINE PRODUCTION THROUGH CHLORINE HYDROXIDE OXIDATION AND PRODUCTION METHOD AND APPLICATION THEREOF |